Vioxx Approved In The U.K. For Osteoarthritis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Vioxx Approved In The U.K. For Osteoarthritis

WHITEHOUSE STATION, NJ -- June 8, 1999 -- Merck & Co., Inc.’s Vioxx(R) (rofecoxib) has been approved in the United Kingdom for symptomatic relief in the treatment of osteoarthritis.

Vioxx will be available immediately. The U.K. is the first country in the European Union to approve Vioxx.

Vioxx works by inhibiting the COX-2 enzyme that triggers pain and inflammation, while sparing a related enzyme (COX-1) that helps maintain the normal stomach lining. In general, certain nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, block both enzymes. These medications treat pain and inflammation, but may damage the stomach lining, potentially leading to ulcers in some patients.

Vioxx is available in the U.S., Mexico, Colombia and Peru for the treatment of osteoarthritis, management of acute pain in adults, and the treatment of primary dysmenorrhea (severe to moderate menstrual pain).

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities